We are a nonprofit policy think tank and field catalyst. We inform and facilitate systems change so mothers, children, and families have the best opportunity to thrive.
Upcoming Maternal Mental Health Events
Featured
We are Fueled by Individual Donors and Organizations like:
Featured Nonprofit Partners
Maternal Mental Health Blog Posts
Featured
A new study shows that a low-dose injection of eskatamine given after childbirth reduces major depressive episodes in those with depression during pregnancy by about 75% at 42 days postpartum. Low-dose ketamine or esketamine has previously been shown to reduce depression in mothers having a cesarean delivery but had excluded mothers with depression during pregnancy from the study.
This week, the first Digital therapeutics (DTx) for maternal mental health, MamaLift Plus™, was approved by the FDA. The treatment, developed by Curio, was studied by randomized control trial. Patients with mild to moderate postpartum depression who used the treatment improved by four or more points on the Edinburgh Postnatal Depression Scale (EPDS).
Today, Congress introduced a resolution declaring May 5-11, 2024 “Maternal Mental Health Awareness Week” - marking the first time Congress has officially recognized Maternal Mental Health Awareness.